Overview

Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy

Status:
Temporarily not available

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The aim of this study is to investigate the efficacy and safety of Tarceva versus combination of Gemcitabine plus Cisplatin as neoadjuvant treatment in patients with stage IIIA-N1,N2 NSCLC with EGFR activating mutation in exon 19 or 21.

Details

Lead Sponsor:

Shanghai Chest Hospital

Collaborators:

Guangdong General Hospital
Guangdong Provincial People's Hospital
Shanghai Pulmonary Hospital, Shanghai, China

Treatments:

Cisplatin
Erlotinib Hydrochloride
Gemcitabine